Fig. 4
From: Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis
Protein-level drug target identification. (A) The forest plot exhibits MR results of all protein-disease pairs with available pQTL data. The center of the error bars represents the odds ratio of MG, and per 1-standard-deviation increase in protein levels, which is calculated by Wald ratio (1 SNP) or IVW (> 1 SNP). MR analyses are based on three pQTL datasets (Zheng et al., Ferkingstad et al., Sun et al.), which can be distinguished by background color. (B) Protein-protein interaction (PPI) results of (i) TNFSF12, (ii) PRSS36, and (iii) CD226. (C) Serum levels of TNFSF12, TNFSF13, and TNFSF13B detected by ELISA experiments. (D) Schematic illustration of promising drug targets with its targeted medications and signal pathways. PPI, protein-protein interaction; ELISA, enzyme-linked immunosorbent assay; OR, odds ratio; 95% CI, 95% confidential interval
Supporting information